# A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

> **NCT05671653** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** PF-07081532
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT05671653
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-19
- **Primary completion:** 2023-11-03
- **Final completion:** 2023-11-03
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05671653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05671653, "A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05671653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*